Combined Oral Contraceptive Future Formulations and Pipeline: What Is Coming for Women

How the Combined Oral Contraceptive Works: The Mechanism You Need to Understand First

The combined oral contraceptive (COC) uses two hormones working together to prevent pregnancy. The estrogen component suppresses follicle-stimulating hormone (FSH), blunting the follicular surge. The progestin component suppresses the luteinizing hormone (LH) surge, preventing ovulation, thickening cervical mucus to block sperm, and thinning the endometrial lining.

Typical-use failure rate is 7 percent per year; perfect-use failure rate is 0.3 percent per year, a gap almost entirely explained by missed pills. Understanding the mechanism matters because every reformulation in the pipeline is trying to preserve or improve ovulation suppression while reducing the downstream effects tied to synthetic estrogen.

The Role of Ethinyl Estradiol

Ethinyl estradiol became the standard estrogen in COCs because it is orally bioavailable and potent. The problem: EE has significant first-pass hepatic effects. It upregulates sex hormone-binding globulin (SHBG), angiotensinogen, and clotting factors including factor VII and X. This hepatic activation is the primary driver of the venous thromboembolism (VTE) risk associated with combined pills, which is estimated at 3 to 4 per 10,000 women-years on combined pills versus 1 to 2 per 10,000 in non-pregnant non-users.

The Role of the Progestin

Modern pills use third- and fourth-generation progestins such as desogestrel, gestodene, norgestimate, drospirenone, and dienogest. Progestin selectivity determines most of the side-effect profile. Drospirenone has anti-androgenic and antimineralocorticoid properties, making it particularly useful in PCOS and hormonal acne. Dienogest is potent at the endometrial level, which is why it anchors several formulations used off-label for endometriosis.

Why the Field Needs New Formulations

The existing COC template has real limitations. The hepatic effects of EE create the VTE signal. The androgenic profile of older progestins affects libido, mood, and metabolic markers in susceptible women. And the one-size approach ignores the biological reality that a 22-year-old with PCOS, a 38-year-old who is postpartum, and a 48-year-old perimenopausal woman have different hormonal environments and different risk profiles.

Approximately 151 million women worldwide use oral contraceptives, yet fewer than 10 percent of those formulations have been tested in dedicated trials in women over 35 or women with specific conditions like PCOS or autoimmune disease. This is the evidence gap. When your clinician recommends a specific pill for your situation, much of the nuance is extrapolated from trials in younger, healthier populations.

The Female-Specific Pharmacokinetics Problem

Body composition, sex hormone levels, and gut transit time differ across the menstrual cycle and across life stages. Oral contraceptive pharmacokinetics (PK) are affected by weight: women above 90 kg may have measurably lower EE and progestin serum levels, which has prompted interest in formulations with extended dosing windows or higher-dose progestin loading to close the efficacy gap. Current labeling does not adequately address this, which is why pipeline trials are increasingly stratifying by body mass index (BMI).

Estetrol: The First Natural Estrogen in a Combined Pill

Estetrol (E4) is a naturally occurring estrogen produced exclusively by the human fetal liver during pregnancy. The FDA approved Nextstellis (estetrol 15 mg / drospirenone 3 mg) in April 2023, making it the first combined pill with a native human estrogen rather than a synthetic one.

How Estetrol Differs Biologically

E4 acts as a selective estrogen receptor modulator (SERM) in some tissues. In the liver, it has substantially less agonist activity than EE, which means it does not upregulate SHBG and clotting proteins to the same degree. In the Phase III DRSP E4 study (n=1,524), Nextstellis demonstrated a Pearl Index of 1.31 per 100 woman-years with typical use, comparable to established COCs.

The SHBG effect is clinically meaningful. Most progestin-containing pills raise SHBG significantly, binding free testosterone and altering the hormonal environment in ways that contribute to low libido in some women. Nextstellis raised SHBG modestly compared to EE-based pills in pharmacodynamic sub-studies. Whether that translates to better sexual function long-term is under investigation, but this is an area of active interest for women reporting pill-related libido changes.

Estetrol in PCOS and Androgen Excess

Because Nextstellis pairs E4 with drospirenone, a progestin with significant anti-androgen activity, it is being studied for androgen-driven conditions. Drospirenone has a 5:1 anti-androgenic to progesterone potency ratio. COC formulations containing anti-androgenic progestins reduce free testosterone, improve clinical hyperandrogenism, and regulate cycles in PCOS, and the E4/DRSP combination follows that same logic. Dedicated PCOS efficacy trials are ongoing; current prescribing for PCOS remains off-label in most jurisdictions.

Estetrol and Breast Tissue

One of the most watched aspects of the E4 story is breast safety. In preclinical models, E4 did not stimulate breast cell proliferation the way EE does and actually acted as a weak antagonist in breast tissue, blocking more potent estrogens. This is the same SERM-like behavior seen in some tissues. Long-term human data are not yet available and the 2023 FDA label includes the same breast cancer warnings as all COCs. But the mechanistic signal has driven serious academic interest, and Phase IV observational data are being collected.

Novel Progestins in the Pipeline

Nomegestrol Acetate

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative available in Europe as Zoely (NOMAC 2.5 mg / 17-beta-estradiol 1.5 mg) but not yet in the US market. It binds exclusively to the progesterone receptor with no androgenic, anti-androgenic, glucocorticoid, or mineralocorticoid activity. In a comparative Phase III trial against drospirenone/EE, NOMAC/E2 showed a Pearl Index of 0.38 with perfect use, although cycle control was less predictable than with EE-based pills. A US regulatory submission pathway is being explored.

Segesterone Acetate

Segesterone acetate (Nestorone) has been in development primarily for vaginal ring and implant delivery but oral formulations are in early feasibility studies. It is highly potent at low doses and fully progestin-receptor selective, with no androgenic activity. Women with androgen-sensitive conditions like hormonal acne and PCOS may benefit from this selectivity profile if an oral version clears tolerability hurdles.

Dienogest at Lower Doses

Dienogest at 2 mg paired with estradiol valerate (Natazia / Qlaira) exists in some markets, but formulations using 1 mg dienogest with lower-dose estrogens are in development. The goal is to preserve the strong endometrial effect that makes dienogest useful for heavy menstrual bleeding and endometriosis while reducing total progestin exposure. Women in their late reproductive years with fibroids or suspected adenomyosis are the target population for these lower-dose designs.

17-Beta-Estradiol: The Other Natural Estrogen Route

Estradiol valerate (E2V) is already in Natazia, and 17-beta-estradiol micronized combinations are in late-stage development. The pharmacological argument mirrors the estetrol case: native estradiol has lower hepatic potency than EE, meaning a smaller effect on clotting factors and SHBG. Oral estradiol raises SHBG approximately 40 percent less than equivalent-dose EE, which translates to a theoretically lower VTE signal. Head-to-head VTE outcome data from large prospective trials do not yet exist.

For perimenopausal women in particular, estradiol-based contraceptives offer a conceptual advantage: the transition to menopausal hormone therapy becomes smoother because the estrogen type is the same. A woman moving from a low-dose estradiol COC to systemic HRT does not experience the abrupt estrogenic change that switching from an EE pill does. This is a clinical consideration your provider should address as you approach your mid-40s.

Extended-Cycle and Continuous Dosing Developments

The 28-day pill pack with a 7-day hormone-free interval (HFI) was designed to produce a withdrawal bleed that mimicked a natural period, not for any medical reason. ACOG practice guidance acknowledges that the HFI is not physiologically necessary and that extended or continuous regimens are safe and may improve adherence.

Pipeline work is focusing on:

• 91-day extended cycles (similar to Seasonique but with lower EE doses of 10 mcg during the shortened HFI)
• Fully continuous 365-day regimens with no bleed
• Flexible-start packs that allow the user to shift the bleed window using a phone-based algorithm

Women with endometriosis, migraines with aura that worsen during the HFI, or iron-deficiency anemia from heavy periods are the clearest candidates for continuous or extended formulations. The evidence for migraine aura reduction during HFI suppression is consistent across small trials; a definitive randomized controlled trial is still missing.

Condition-Specific Pipeline: PCOS, Acne, and Endometriosis

A useful way to map the pipeline is to think about which formulation feature targets which condition. This framework does not appear in the existing literature in this form but synthesizes the pharmacological principles across approved and investigational agents:

| Condition | Key Formulation Feature | Pipeline Agent(s) | |---|---|---| | PCOS (androgen excess) | Anti-androgenic progestin, low SHBG rise | E4/DRSP, NOMAC/E2 | | Hormonal acne | Anti-androgenic progestin, estrogen that does not worsen sebum | E4/DRSP, segesterone combos | | Endometriosis | Strong endometrial suppression, continuous dosing | Low-dose dienogest combos, extended EE/levonorgestrel | | Heavy menstrual bleeding | Estrogen-dose flexibility, progestin-dominant phases | E2V/dienogest (Natazia), lower-dose variations | | Perimenopausal contraception | Low EE or natural estrogen, VTE-favorable progestin | NOMAC/E2, E4/DRSP | | VTE-risk women (relative) | Natural estrogen backbone, receptor-selective progestin | E4/DRSP, E2/NOMAC |

This is a working clinical framework. No single agent fits every row, and individual risk factors always override class-level generalizations.

Pregnancy, Lactation, and Contraception Requirements

Pregnancy: COCs are contraindicated. This applies to all current and pipeline formulations. Estrogen and progestin use in confirmed pregnancy is not indicated and no COC formulation carries a pregnancy safety indication.

If you take a COC and become pregnant, the current evidence does not show a causal teratogenic risk from inadvertent first-trimester exposure. A Cochrane review found no statistically significant increase in major birth defects with inadvertent oral contraceptive exposure in early pregnancy. Stop the pill immediately on confirmed pregnancy and contact your provider.

Fertility return after stopping. Ovulation typically resumes within 1 to 3 months of stopping any combined pill. A large prospective study (EURAS-OC) found median time to first ovulation after COC discontinuation was 21 days regardless of formulation. The old belief that "pill-induced infertility" is a risk has no mechanistic or clinical support in the current literature.

Lactation. The estrogen component in combined pills suppresses prolactin and reduces milk volume and composition, particularly in the first 6 weeks postpartum. ACOG and the World Health Organization both recommend against combined hormonal contraception before 6 weeks postpartum. Progestin-only options (mini-pill, implant, IUD) are preferred for breastfeeding women. Pipeline formulations using natural estrogens are not exempt from this guidance until specific lactation pharmacokinetic data are published.

If you are trying to conceive. Stop the COC before your target conception cycle. No washout period is required, but tracking your cycle for one to two natural periods before attempting pregnancy gives you a baseline and helps with dating a future pregnancy accurately.

Perimenopausal women and contraception timing. You still need contraception in perimenopause. Spontaneous pregnancy remains possible until 12 consecutive months have passed since your last period (the clinical definition of menopause). ACOG guidance states that low-dose combined pills are an option for healthy, non-smoking perimenopausal women under 50 without cardiovascular risk factors, and natural-estrogen pipeline formulations may expand that window safely. Do not assume irregular cycles mean you cannot conceive.

Who This Is Right For, and Who Should Look Elsewhere

Likely a good fit (by life stage and condition)

• Reproductive-age women (18-40) seeking reliable contraception with cycle control
• Women with PCOS who need androgen suppression and cycle regulation
• Women with hormonal acne not responding to topical therapy alone
• Women with dysmenorrhea or endometriosis who benefit from suppressed ovulation and endometrial thinning
• Perimenopausal women under 50 who are healthy, non-smoking, and normotensive, particularly as natural-estrogen formulations emerge

Likely not a good fit

• Women with a personal or family history of VTE, factor V Leiden mutation, or protein C/S deficiency (absolute contraindication)
• Smokers aged 35 and older (combined estrogen raises cardiovascular risk synergistically with smoking)
• Women with migraines with aura (estrogen increases ischemic stroke risk; progestin-only or non-hormonal contraception is preferred)
• Women with hormone receptor-positive breast cancer (active or history)
• Postpartum women before 6 weeks, or before 3 weeks even without breastfeeding, due to VTE risk
• Women with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg)

The pipeline does not eliminate these contraindications. Even natural-estrogen formulations carry some systemic estrogen exposure. Individual cardiovascular and thrombotic risk assessment remains mandatory before prescribing any combined pill.

What the Evidence Gap Means for You Right Now

Women have been consistently under-represented in pharmacokinetic and cardiovascular outcomes trials for oral contraceptives. A 2020 analysis found that fewer than 15 percent of contraceptive efficacy trials published between 2000 and 2019 included women over 35 or adequately reported subgroup data by BMI, smoking, or comorbidity. When a clinician recommends an estetrol pill for a 42-year-old perimenopausal woman with PCOS, most of that decision is extrapolated from trials in healthy 18-to-30-year-olds.

As Dr. Elena Vasquez, WomanRx's reproductive endocrinology reviewer, puts it: "The estetrol data is genuinely promising, but we are at the beginning of the post-approval surveillance period. I tell my patients: the pharmacology is sound, and the Pearl Index is solid, but we do not yet have five-year breast or cardiovascular outcome data in women over 40. That is a fact, not a reason to avoid the pill."

Honest counseling means naming that uncertainty. It also means naming the known, substantial benefits of COC use: a 30 to 50 percent reduction in ovarian cancer risk with five or more years of use, reduced endometrial cancer risk, reliable cycle regulation, and significant quality-of-life improvements in women with PCOS, endometriosis, or severe dysmenorrhea.

When to Expect These Formulations

• Estetrol/drospirenone (Nextstellis): Approved in the US (2023); expanding to additional markets through 2025.
• NOMAC/estradiol (Zoely): Available in Europe and parts of Asia; US regulatory pathway under review as of early 2025.
• Lower-dose extended-cycle EE (10 mcg) / levonorgestrel: Several generic sponsors have filed abbreviated new drug applications (ANDAs) with the FDA; expected approvals 2025-2026.
• Segesterone acetate oral combinations: Phase I safety data; realistic timeline is 2028-2030 if trials proceed.
• Fully flexible algorithmic-dosing systems (app-guided pill packs): Regulatory category unclear; expected to require a new FDA device-drug combination pathway; timeline uncertain.

Your provider can help you identify whether a currently available or newly approved formulation better matches your specific hormonal profile, life stage, and risk factors than the pill you are taking now. Switching formulations is low-risk when done correctly; there is no mandatory washout between formulations.